Industry change
Novo Nordisk partners with Anthropic for drug discovery
- Published
- Source
- Novo Nordisk press release
Summary
On September 16, Novo Nordisk announced a collaboration with Anthropic. The company will pilot Claude Science in selected R&D workflows to speed up drug discovery and use Anthropic's models to strengthen AI-driven software development in-house. CEO Mike Doustdar said the partnership will supercharge the company's R&D organisation. The collaboration is designed with data governance and human oversight, building on Novo's earlier work with OpenAI and AWS.
Why it matters for our work
A clear example of frontier models entering long-cycle research work such as pharmaceutical R&D. If research-to-product cycles shrink, it could change how research and supporting staff work, though the outlook is stated by the companies themselves.
Translated from the Korean original. Summaries may be translated and edited. Commentary reflects our perspective; forecasts remain the source’s views.